Barclays Reinstates Tarsus Pharmaceuticals (TARS) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts TARS Hot Sheet
Price: $72.08 +2.24%
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
11 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
Barclays analyst Glen Santangelo reinstates coverage on Tarsus Pharmaceuticals (NASDAQ: TARS) with a Overweight rating and a price target of $110.00.
For an analyst ratings summary and ratings history on Tarsus Pharmaceuticals click here. For more ratings news on Tarsus Pharmaceuticals click here.
Shares of Tarsus Pharmaceuticals closed at $78.23 yesterday.
You May Also Be Interested In
- HSBC Starts Airtel Money (AMC:LN) at Buy
- KeyBanc Starts Astronics (ATRO) at Sector Weight
- Barclays Starts Rush Street Interactive (RSI) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
